Capstone Therapeutics Corp. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2014; filed November 13, 2014. The provided filing identifies the registrant as Capstone Therapeutics Corp., not Capstone Holding Corp. The financial statements are unaudited and consolidate the Company and its 60%-owned LipimetiX Development LLC subsidiary.
Business Context and Reporting Period
Capstone is a biotechnology company operating under a substantially virtual model. It has no revenue-producing operations following the 2003 sale of its Bone Device Business and is focused primarily on developing AEM-28 and related Apo E mimetic peptides through LipimetiX Development LLC. In August 2014, the Company terminated its AZX100 license and returned the related intellectual property to the licensor.
LipimetiX’s Phase 1a AEM-28 trial in Australia, involving 36 patients, was completed in August 2014, with the Medical Safety Committee observing an acceptable safety profile. The Phase 1b/2a trial commenced in June 2014 and was expected to include no more than 15 patients. The initial development plan was expected to conclude in the fourth quarter of 2014.
Financial Position and Results
| Metric | Three Months Ended September 30, 2014 | Three Months Ended September 30, 2013 | Nine Months Ended September 30, 2014 | Nine Months Ended September 30, 2013 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| General and administrative expense | $373,000 | $245,000 | $1.047 million | $956,000 |
| Research and development expense | $865,000 | $958,000 | $2.667 million | $2.619 million |
| Total operating expenses | $1.238 million | $1.203 million | $3.714 million | $3.575 million |
| Net loss attributable to Capstone stockholders | $1.234 million | $1.202 million | $3.647 million | $3.206 million |
| Loss per share, basic and diluted | $0.03 | $0.03 | $0.09 | $0.08 |
No revenue, gross profit, or operating margin was reported. The nine-month operating loss margin cannot be meaningfully calculated because the Company had no revenue.
- Cash and cash equivalents: $3.111 million at September 30, 2014, down from $6.258 million at December 31, 2013. Approximately $89,000 was reserved for LipimetiX and unavailable for general corporate use.
- Current assets: $3.388 million; current liabilities: $471,000; implied current ratio approximately 7.2x.
- Total assets: $4.093 million, compared with $7.317 million at year-end 2013.
- Stockholders’ equity: $3.622 million, compared with $7.217 million at year-end 2013. Accumulated deficit was $185.665 million.
- Debt: No debt balance was reported at September 30, 2014. A revolving loan agreement permitted advances to the joint venture of up to a net $500,000, due June 30, 2015; no advances were outstanding at quarter-end.
- Operating cash flow: $3.147 million used during the first nine months of 2014, compared with $3.026 million used in the comparable 2013 period.
- Investing and financing cash flow: No investing or financing cash flow was reported for the first nine months of 2014.
Material Changes Versus the Prior Comparable Period
- Third-quarter total operating expenses increased approximately 3% year over year, primarily because G&A expense increased from $245,000 to $373,000, largely due to qui tam litigation costs. R&D expense decreased from $958,000 to $865,000.
- Nine-month total operating expenses increased approximately 4% to $3.714 million. G&A increased approximately 10%, while R&D increased approximately 2%.
- Nine-month net loss attributable to Capstone stockholders increased approximately 14% to $3.647 million, primarily reflecting lower other income and the allocation of 100% of joint venture losses to the Company.
- Cash declined by $3.147 million during the first nine months, while current liabilities increased from $100,000 to $471,000.
- The Company adopted the FASB guidance eliminating development-stage entity reporting requirements; management reported no financial statement impact.
- The Company established a Tax Benefit Preservation Plan in June 2014 and designated Series A Preferred Stock. The plan expires June 24, 2016 and may delay or prevent a change in control without Board approval.
Guidance, Outlook, Risks, and Unusual Items
- Management estimated 2014 cash expenditures of approximately $4.0 million, including approximately $2.5 million for LipimetiX and approximately $500,000 expected from general Company funds or other sources, potentially including an Australian refundable R&D tax credit.
- Management stated that cash and short-term investments at September 30, 2014 were expected to satisfy projected cash and working-capital requirements for the next twelve months. Additional capital would be required to extend AEM-28 development beyond the initial Phase 1a and Phase 1b/2a trials or to complete later-stage development and regulatory activities.
- LipimetiX had incurred AUD $920,000 of potentially qualifying Australian R&D expenditures through September 30, 2014. No refundable tax credit was recorded because eligibility and the amount of qualifying expenditures remained uncertain.
- The Company remains subject to a long-running qui tam lawsuit relating to its former bone-growth-stimulation business. No trial date had been set, discovery was open, and management had not recorded a material loss provision. A judgment exceeding available resources could materially impair liquidity and threaten continuation of the business.
- The Company reduced its internal operations to a virtual model and had previously reduced employees from 18 to 2. Future spending depends on LipimetiX development decisions and litigation activity.
- Key development risks include unfavorable clinical or preclinical results, regulatory delays or failure, competition, intellectual-property impairment, insufficient funding, and the ability to secure development or licensing arrangements.
Important Facts for Investors to Verify
- Confirm the registrant identity and ticker relationship because the supplied request names Capstone Holding Corp., while the filing names Capstone Therapeutics Corp.
- Review subsequent results from the AEM-28 Phase 1b/2a trial and determine whether the planned 2014 development milestones were achieved.
- Assess cash runway against ongoing operating losses, clinical development needs, potential litigation costs, and the absence of operating revenue.
- Monitor the qui tam litigation, including any trial date, settlement discussions, judgment exposure, or changes to the Company’s loss assessment.
- Verify whether the Australian R&D tax credit was ultimately claimed, recognized, or received.
- Evaluate the implications of the AZX100 license termination, the Tax Benefit Preservation Plan, and the Company’s reliance on the LipimetiX joint venture.